Epilepsy Research

SCIE

國(guó)際簡(jiǎn)稱：EPILEPSY RES 參考譯名：癲癇研究

主要研究方向：醫(yī)學(xué)-臨床神經(jīng)學(xué) 非預(yù)警期刊審稿周期：一般,3-8周約15.6周

《癲癇研究》(Epilepsy Research)是一本由Elsevier出版的以醫(yī)學(xué)-臨床神經(jīng)學(xué)為研究特色的國(guó)際期刊，發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評(píng)論文章和綜述文章，及時(shí)報(bào)道該領(lǐng)域相關(guān)理論、實(shí)踐和應(yīng)用學(xué)科的最新發(fā)現(xiàn)，旨在促進(jìn)該學(xué)科領(lǐng)域科學(xué)信息的快速交流。該期刊是一本未開放期刊，近三年沒有被列入預(yù)警名單。

4區(qū) 中科院分區(qū)
Q3 JCR分區(qū)
135 年發(fā)文量
2 IF影響因子
未開放 是否OA
105 H-index
1987 創(chuàng)刊年份
Monthly 出版周期
English 出版語(yǔ)言

Epilepsy Research provides for publication of high quality articles in both basic and clinical epilepsy research, with a special emphasis on translational research that ultimately relates to epilepsy as a human condition. The journal is intended to provide a forum for reporting the best and most rigorous epilepsy research from all disciplines ranging from biophysics and molecular biology to epidemiological and psychosocial research. As such the journal will publish original papers relevant to epilepsy from any scientific discipline and also studies of a multidisciplinary nature. Clinical and experimental research papers adopting fresh conceptual approaches to the study of epilepsy and its treatment are encouraged. The overriding criteria for publication are novelty, significant clinical or experimental relevance, and interest to a multidisciplinary audience in the broad arena of epilepsy. Review articles focused on any topic of epilepsy research will also be considered, but only if they present an exceptionally clear synthesis of current knowledge and future directions of a research area, based on a critical assessment of the available data or on hypotheses that are likely to stimulate more critical thinking and further advances in an area of epilepsy research.

[ 查看全部 ]

投稿咨詢加急咨詢

Epilepsy Research期刊信息

ISSN：0920-1211
出版語(yǔ)言：English
是否OA：未開放
E-ISSN：1872-6844
出版地區(qū)：NETHERLANDS
是否預(yù)警：否
出版商：Elsevier
出版周期：Monthly
創(chuàng)刊時(shí)間：1987
開源占比：0.1213
Gold OA文章占比：20.72%
OA被引用占比：0.0894...
出版國(guó)人文章占比：0.1
出版撤稿占比：0
研究類文章占比：92.59%

Epilepsy Research CiteScore評(píng)價(jià)數(shù)據(jù)（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數(shù)

4.4

0.71

0.746

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Neurology (clinical)	Q2	173 / 400	56%
大類：Medicine 小類：Neurology	Q2	91 / 192	52%

名詞解釋：CiteScore 是衡量期刊所發(fā)表文獻(xiàn)的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個(gè)指標(biāo)。當(dāng)年CiteScore 的計(jì)算依據(jù)是期刊最近4年（含計(jì)算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻(xiàn)數(shù)。例如，2022年的 CiteScore 計(jì)算方法為：2022年的 CiteScore =2019-2022年收到的對(duì)2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻(xiàn)數(shù)量注：文獻(xiàn)類型包括：文章、評(píng)論、會(huì)議論文、書籍章節(jié)和數(shù)據(jù)論文。

Epilepsy Research中科院評(píng)價(jià)數(shù)據(jù)

中科院 2023年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	CLINICAL NEUROLOGY 臨床神經(jīng)病學(xué)	4區(qū)

中科院 2022年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	CLINICAL NEUROLOGY 臨床神經(jīng)病學(xué)	4區(qū)

中科院 2021年12月舊的升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	CLINICAL NEUROLOGY 臨床神經(jīng)病學(xué)	4區(qū)

中科院 2021年12月基礎(chǔ)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	CLINICAL NEUROLOGY 臨床神經(jīng)病學(xué)	4區(qū)

中科院 2021年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	CLINICAL NEUROLOGY 臨床神經(jīng)病學(xué)	4區(qū)

中科院 2020年12月舊的升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	CLINICAL NEUROLOGY 臨床神經(jīng)病學(xué)	4區(qū)

Epilepsy Research JCR評(píng)價(jià)數(shù)據(jù)（2023-2024年最新版）

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：CLINICAL NEUROLOGY	SCIE	Q3	170 / 277	38.8%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：CLINICAL NEUROLOGY	SCIE	Q3	166 / 278	40.47%

Epilepsy Research歷年數(shù)據(jù)統(tǒng)計(jì)

影響因子

中科院分區(qū)

Epilepsy Research中國(guó)學(xué)者發(fā)文選摘

1、Bioinformatics and network pharmacology analysis of drug targets and mechanisms related to the comorbidity of epilepsy and migraine
Author: Shen, Ziyi; Pu, Shengxiong; Cao, Xing; Tang, Ming; Wang, Shenglin; Bai, Dazhang; Jiang, Guohui

Journal: EPILEPSY RESEARCH. 2023; Vol. 189, Issue , pp. -. DOI: 10.1016/j.eplepsyres.2022.107066
2、Efficacy and safety of traditional Chinese medicine for the treatment of epilepsy: A updated meta-analysis of randomized controlled trials
Author: Lu, Haimei; Luo, Mengxian; Chen, Rongrong; Luo, Yijun; Xi, Anran; Wang, Keer; Xu, Zhenghao

Journal: EPILEPSY RESEARCH. 2023; Vol. 189, Issue , pp. -. DOI: 10.1016/j.eplepsyres.2022.107075
3、Mendelian randomization approach shows no causal effects of gestational age on epilepsy in offspring
Author: Guo, Xingzhi; Tang, Peng; Zhang, Lina; Cui, Junhao; Li, Rui

Journal: EPILEPSY RESEARCH. 2023; Vol. 191, Issue , pp. -. DOI: 10.1016/j.eplepsyres.2023.107102
4、Long-term outcomes of classic and novel anti-seizure medication in a kainate-induced model of chronic epilepsy
Author: Li, Jing; Sha, Longze; Xu, Qi

Journal: EPILEPSY RESEARCH. 2023; Vol. 191, Issue , pp. -. DOI: 10.1016/j.eplepsyres.2023.107095
5、Serum concentration of high-mobility group box 1, Toll-like receptor 4 as biomarker in epileptic patients
Author: Yue, Zongwei; Tang, Jingyi; Peng, Sudan; Cai, Xuehua; Rong, Xiaoming; Yang, Lianhong

Journal: EPILEPSY RESEARCH. 2023; Vol. 192, Issue , pp. -. DOI: 10.1016/j.eplepsyres.2023.107138
6、Increased expression of DOC2A in human and rat temporal lobe epilepsy
Author: Xiao Hu, Jun Tang, Xiaofang Lan, Xiujuan Mi

Journal: EPILEPSY RESEARCH, 2019, Vol.151, 78-84, DOI:10.1016/j.eplepsyres.2019.02.008
7、Protective effects of lycopene on kainic acid-induced seizures
Author: Sen Li, Zhen Luo, Bingyi Lu, Shangzhou Xia, Chen Li, Xiao Guan, Jingchen Zhang, Kai Huang, Furong Xian

Journal: EPILEPSY RESEARCH, 2019, Vol.151, 1-6, DOI:10.1016/j.eplepsyres.2019.01.010
8、Corrigendum to “Lithium affects rat hippocampal electrophysiology and epileptic seizures in a dose dependent manner” [Epilepsy Res. 146 (2018) 112–120]
Author: Guohui Jiang, Pu Tianqiang, Zhimin Li, Xiaodong Zhang, Ruijiao Zhou, Xing Cao, JuminG Yu, Xiaoming Wang

Journal: EPILEPSY RESEARCH, 2019, Vol., , DOI:10.1016/j.eplepsyres.2018.12.002